Urovysion™ testing can lead to early identification of intravesical therapy failure in patients with high risk non-muscle invasive bladder cancer
Purpose: In this study, we investigated the ability of UroVysion™ to assess response to intravesical therapy in patients with high risk superficial bladder tumors. Materials and methods: We performed a retrospective review of patients undergoing intravesical therapy for high risk superfici...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sociedade Brasileira de Urologia
2009-12-01
|
| Series: | International Brazilian Journal of Urology |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382009000600005 |
| _version_ | 1828736277795569664 |
|---|---|
| author | Jared M. Whitson Anna B. Berry Peter R. Carroll Badrinath R. Konety |
| author_facet | Jared M. Whitson Anna B. Berry Peter R. Carroll Badrinath R. Konety |
| author_sort | Jared M. Whitson |
| collection | DOAJ |
| description | Purpose: In this study, we investigated the ability of UroVysion™ to assess response to intravesical therapy in patients with high risk superficial bladder tumors. Materials and methods: We performed a retrospective review of patients undergoing intravesical therapy for high risk superficial bladder tumors. Urine specimens were collected for UroVysion™ analysis before and immediately after a course of intravesical therapy. Cytology and cystoscopy were performed six weeks after treatment, using either a positive cytology or visible abnormality on cystoscopy as a prompt for biopsy. The operating characteristics of the UroVysion™ test were then determined. Results: 41 patients were identified in whom 47 cycles of induction and 41 cycles of maintenance intravesical therapy were given during the study period. This yielded a total of 88 treatment and evaluation cycles. Median follow-up was 9 months per induction (range 1-21 months) and 13 months per patient (range 1-25 months). A total of 133 urine samples were collected for UroVysion™ of which 40 were positive. Based upon standard clinical evaluation, 41 biopsies were performed which detected 20 recurrences. UroVysion™ testing performed immediately upon completion of therapy for the 41 patients undergoing biopsy yielded a sensitivity, specificity, and accuracy of 85%, 61%, and 71%. Conclusions: The use of UroVysion™ following intravesical therapy for high-risk superficial bladder tumors helps to identify patients at high risk of refractory or recurrent disease who should undergo immediate biopsy under anesthesia. |
| first_indexed | 2024-04-12T23:22:37Z |
| format | Article |
| id | doaj.art-44b128331a8944aa8ae8966f9f9dc5b0 |
| institution | Directory Open Access Journal |
| issn | 1677-5538 1677-6119 |
| language | English |
| last_indexed | 2024-04-12T23:22:37Z |
| publishDate | 2009-12-01 |
| publisher | Sociedade Brasileira de Urologia |
| record_format | Article |
| series | International Brazilian Journal of Urology |
| spelling | doaj.art-44b128331a8944aa8ae8966f9f9dc5b02022-12-22T03:12:29ZengSociedade Brasileira de UrologiaInternational Brazilian Journal of Urology1677-55381677-61192009-12-0135666467210.1590/S1677-55382009000600005Urovysion™ testing can lead to early identification of intravesical therapy failure in patients with high risk non-muscle invasive bladder cancerJared M. WhitsonAnna B. BerryPeter R. CarrollBadrinath R. KonetyPurpose: In this study, we investigated the ability of UroVysion™ to assess response to intravesical therapy in patients with high risk superficial bladder tumors. Materials and methods: We performed a retrospective review of patients undergoing intravesical therapy for high risk superficial bladder tumors. Urine specimens were collected for UroVysion™ analysis before and immediately after a course of intravesical therapy. Cytology and cystoscopy were performed six weeks after treatment, using either a positive cytology or visible abnormality on cystoscopy as a prompt for biopsy. The operating characteristics of the UroVysion™ test were then determined. Results: 41 patients were identified in whom 47 cycles of induction and 41 cycles of maintenance intravesical therapy were given during the study period. This yielded a total of 88 treatment and evaluation cycles. Median follow-up was 9 months per induction (range 1-21 months) and 13 months per patient (range 1-25 months). A total of 133 urine samples were collected for UroVysion™ of which 40 were positive. Based upon standard clinical evaluation, 41 biopsies were performed which detected 20 recurrences. UroVysion™ testing performed immediately upon completion of therapy for the 41 patients undergoing biopsy yielded a sensitivity, specificity, and accuracy of 85%, 61%, and 71%. Conclusions: The use of UroVysion™ following intravesical therapy for high-risk superficial bladder tumors helps to identify patients at high risk of refractory or recurrent disease who should undergo immediate biopsy under anesthesia.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382009000600005bladder neoplasmssuperficialBCGinterferonschemotherapyfollow-up |
| spellingShingle | Jared M. Whitson Anna B. Berry Peter R. Carroll Badrinath R. Konety Urovysion™ testing can lead to early identification of intravesical therapy failure in patients with high risk non-muscle invasive bladder cancer International Brazilian Journal of Urology bladder neoplasms superficial BCG interferons chemotherapy follow-up |
| title | Urovysion™ testing can lead to early identification of intravesical therapy failure in patients with high risk non-muscle invasive bladder cancer |
| title_full | Urovysion™ testing can lead to early identification of intravesical therapy failure in patients with high risk non-muscle invasive bladder cancer |
| title_fullStr | Urovysion™ testing can lead to early identification of intravesical therapy failure in patients with high risk non-muscle invasive bladder cancer |
| title_full_unstemmed | Urovysion™ testing can lead to early identification of intravesical therapy failure in patients with high risk non-muscle invasive bladder cancer |
| title_short | Urovysion™ testing can lead to early identification of intravesical therapy failure in patients with high risk non-muscle invasive bladder cancer |
| title_sort | urovysion 8482 testing can lead to early identification of intravesical therapy failure in patients with high risk non muscle invasive bladder cancer |
| topic | bladder neoplasms superficial BCG interferons chemotherapy follow-up |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382009000600005 |
| work_keys_str_mv | AT jaredmwhitson urovysion8482testingcanleadtoearlyidentificationofintravesicaltherapyfailureinpatientswithhighrisknonmuscleinvasivebladdercancer AT annabberry urovysion8482testingcanleadtoearlyidentificationofintravesicaltherapyfailureinpatientswithhighrisknonmuscleinvasivebladdercancer AT peterrcarroll urovysion8482testingcanleadtoearlyidentificationofintravesicaltherapyfailureinpatientswithhighrisknonmuscleinvasivebladdercancer AT badrinathrkonety urovysion8482testingcanleadtoearlyidentificationofintravesicaltherapyfailureinpatientswithhighrisknonmuscleinvasivebladdercancer |